Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
After the pandemic: perspectives on the future trajectory of COVID-19
There is a realistic expectation that the global effort in vaccination will bring the pandemic
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control …
caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) under control …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA. 2
R Uraki, M Kiso, S Iida, M Imai, E Takashita, M Kuroda… - Nature, 2022 - nature.com
The recent emergence of SARS-CoV-2 Omicron (B. 1.1. 529 lineage) variants possessing
numerous mutations has raised concerns of decreased effectiveness of current vaccines …
numerous mutations has raised concerns of decreased effectiveness of current vaccines …
Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients
A Jayk Bernal, MM Gomes da Silva… - … England Journal of …, 2022 - Mass Medical Soc
Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …
A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus
There is an urgent need for an effective, oral, direct-acting therapeutic to block transmission
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent progression …
An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19
DR Owen, CMN Allerton, AS Anderson… - Science, 2021 - science.org
The worldwide outbreak of COVID-19 caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …
coronavirus 2 (SARS-CoV-2) has become a global pandemic. Alongside vaccines, antiviral …
Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
F Kabinger, C Stiller, J Schmitzová… - Nature structural & …, 2021 - nature.com
Molnupiravir is an orally available antiviral drug candidate currently in phase III trials for the
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
treatment of patients with COVID-19. Molnupiravir increases the frequency of viral RNA …
Molnupiravir in COVID-19: A systematic review of literature
AK Singh, A Singh, R Singh, A Misra - Diabetes & Metabolic Syndrome …, 2021 - Elsevier
Background and aims Molnupiravir is a newer oral antiviral drug that has recently been
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
tested in COVID-19. We aim to conduct a systematic review of literature to find out the …
SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
Dear Editor, Since the first outbreak in late 2019, the RNA genome of SARS-CoV-2 has
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …
been undergoing constant evolution. This is largely attributed to the viral polymerase that is …